摘要
[目的]探讨谷氨酰胺(glutamine,Gln)对肺腺癌A549细胞增殖、迁移及TNF-α、NF-κB表达的影响。[方法]体外培养肺腺癌A549细胞株,CCK-8法检测不同浓度Gln(2、4、8、16、32、64mmol/L)对A549细胞的增殖影响,筛选适宜浓度。Transwell实验检测细胞迁移能力,ELISA法和Western Bolt法分别检测TNF-α、NF-κB p65蛋白表达。[结果 ](1)Gln对A549细胞的作用与干预浓度有关,缺乏Gln时细胞生长受限;低浓度Gln(2、4、8mmol/L)对细胞增殖无明显抑制作用;高浓度Gln(16、32、64mmol/L)作用下抑制作用明显(P〈0.01)并呈时间依赖性,且32mmol/L和64mmol/L两组作用无明显差异(P〉0.05)。(2)与对照组相比,Gln组明显降低A549细胞迁移数;高浓度Gln组明显降低TNF-α、NF-κB p65蛋白的表达(P〈0.01),但32mmol/L和64mmol/L组之间无统计学差异(TNF-α分别为14.671±0.842pg/ml、14.867±1.21pg/ml,NF-κB p65分别为0.548±0.042、0.474±0.077)(P〉0.05)。[结论 ]Gln对肺腺癌A549细胞的作用与浓度有关,32mmol/L可能为最适抑制浓度。Gln可能通过下调TNF-α和NF-κB p65蛋白表达并抑制A549细胞的迁移发挥抗肺腺癌作用。
[Objective]To investigate the effects of glutamine on proliferation,migration and expression of TNF-α and NF-κB in human lung adenocarcinoma A549 cells.[Methods]The cultured lung adenocarcinoma A549 cells were treated with glutamine(0,2,4,8,16,32,64 mmol/L).The cell growth inhibition rate was measured with CCK-8 method;the migration ability of A549 cells was determined by Transwell assay;the expression of TNF-α was detected by ELISA method and NF-κB p65 protein was detected by Western Blot.[Results]The inhibition rates of A549 cells in glutamine 16,32 and 64 mmol/L groups were significantly higher than those in control group and glutamine 2,4,8 mmol/L groups(P0.01),while there was no significant difference between 32 mmol/L and 64 mmol/L groups(P0.05).Compared with the control group,the migration ability of A549 cells in glutamine 32 mmol/L group was significantly reduced;and the expressions of TNF-α and NF-κB p65 protein in in glutamine 16,32 and 64 mmol/L groups were significantly decreased(P〈0.01),but there was no significant difference between 32 mmol/L and 64 mmol/L groups(P〉0.05).[Conclusion]The effect of glutamine on lung adenocarcinoma A549 cells is concentration-dependent,and the optimal inhibitory concentration is 32 mmol/L.The effect of glutamine on lung adenocarcinoma cells may be related to down-regulation of TNF-α and NF-κB p65 in A549 cells.
作者
赖彦
邓述恺
LAI Yan;DENG Shu-kai(Southwest Medical University,Luzhou 646000,China;First Affiliated Hospital,Southwest Medical University ,Luzhou 646000, China)
出处
《肿瘤学杂志》
CAS
2018年第3期213-217,共5页
Journal of Chinese Oncology